Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care oral care Clear all
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066, Pemetrexed, Docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
119
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

NCT05285982
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib (Ofev®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

NCT06794229
View directory record Official record
Conditions
Locally Advanced Renal Cell Carcinoma
Interventions
Zanzalintinib, Nivolumab
Drug
Lead sponsor
Qian Qin
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

NCT06428630
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Reaction
Interventions
dexamethasone oral rinse
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 8, 2026, 5:44 AM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Active, not recruiting Not applicable Interventional

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
View directory record Official record
Conditions
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Interventions
Yoga, Yoga Questionnaire, Symptom Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, Levofloxacin
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

NCT05901831
View directory record Official record
Conditions
Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions
Finerenone, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Surprise, Arizona • Stanford, California • Vallejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 8, 2026, 5:44 AM EDT
Withdrawn Phase 4 Interventional

Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty

NCT06333522
View directory record Official record
Conditions
Arthrofibrosis of Knee
Interventions
Losartan
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 8, 2026, 5:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

NCT07198724
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
Interventions
Elacestrant, Trastuzumab Deruxtecan
Drug
Lead sponsor
Kristina A. Fanucci
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 8, 2026, 5:44 AM EDT
Recruiting Phase 1 Interventional

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT06675123
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, BTK Inhibitor, Computed Tomography, Pacritinib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 4 Interventional

Multimodal Analgesia Effect on Post Surgical Patient

NCT04240626
View directory record Official record
Conditions
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
Interventions
Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Zofran Injection, Scopolamine patch, Ativan, Flexeril Oral Product, Tylenol Suspension
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional Results available

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

NCT04335552
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of care, Hydroxychloroquine, Azithromycin
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Not applicable Interventional

A Pilot Study Swiftsure

NCT05578599
View directory record Official record
Conditions
Ventilated Patients
Interventions
Swiftsure CCS device
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Esthetics of Dental Composite and Adhesive System

NCT03716349
View directory record Official record
Conditions
Cavities of Teeth
Interventions
Pulp vitality testing, Photos, local and/or topical anesthetic, rubber dam, tooth surface cleaned, enamel margins, Adhesive Systems, cavity preparation, Shade selection using Easy Shade 5, Light Curing, Contoured and polished, Consent, Health Questionnaire, xray, Release of medical information signed, Oral Exam, Teeth Assessment, Clinical Assessment, Tokuyama Universal Bond, ScotchBond
Diagnostic Test · Other · Drug + 3 more
Lead sponsor
Erica Teixeira
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Adolescent Adherence to Hormonal Contraception

NCT00584038
View directory record Official record
Conditions
Contraception
Interventions
educational instruction and phone follow-up, educational instruction in clinic
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
1,155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

NCT05195918
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Combination Product
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

NCT01843920
View directory record Official record
Conditions
Scleral Buckling
Interventions
Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
Drug
Lead sponsor
Jason Hsu, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 8, 2026, 5:44 AM EDT
Recruiting Not applicable Interventional

Tongue Proactive Strengthening Exercise Program Following Partial/Hemi Glossectomy and Reconstruction

NCT07110142
View directory record Official record
Conditions
Oral Cancer, Head and Neck Cancer
Interventions
Tongueometer
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease

NCT00792246
View directory record Official record
Conditions
Graft Versus Host Disease, Stem Cell Transplantation
Interventions
voriconazole
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 8, 2026, 5:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

NCT02018861
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 8, 2026, 5:44 AM EDT